首页 › 冒烟型多发性骨髓瘤 › 纽约州 › New York City
New York City NY 冒烟型多发性骨髓瘤临床试验
6项针对 冒烟型多发性骨髓瘤的研究正在 New York City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
招募中
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
招募中3 期
- Memorial Sloan Kettering Cancer Center, New York
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
招募中3 期
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
招募中2 期
- NYU Langone Health Perlmutter Cancer Center, New York
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
招募中
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
招募中观察性研究
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
其他城市的 冒烟型多发性骨髓瘤试验
- Boston, MA6 项研究
- Atlanta, GA5 项研究
- Durham, NC3 项研究
- Columbus, OH3 项研究
- Salt Lake City, UT3 项研究
- Edison, NJ3 项研究
- Houston, TX3 项研究
- Denver, CO3 项研究
New York City的其他研究
- 乳腺癌136 项研究
- 非小细胞肺癌121 项研究
- 癌症（所有类型）109 项研究
- 前列腺癌103 项研究
- 转移性癌症93 项研究
- 结直肠癌78 项研究
- 卵巢癌69 项研究
- 肺癌60 项研究
- 多发性骨髓瘤60 项研究
- 胰腺癌60 项研究
- 子宫内膜癌52 项研究
- 急性髓系白血病51 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。